Skip to main content

Table 7 Treatment progress and changes in the serum carbohydrate antigen 19-9 (CA19-9) level among different stages

From: Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment

Stage

Baseline CA19-9 levels

Post CA19-9 levels

P*

Decreased

P†

Decreased > 20%

P†

All patients

11.23 (6.31, 24.55)

12.88 (7.24, 24.64)

0.144

209 (39.21)

0.186

142 (26.64)

0.072

0

8.87 (5.71, 16.31)

12.02 (7.51, 18.59)

0.303

10 (29.41)

 

5 (14.71)

 

I

9.75 (6.27, 16.88)

12.58 (7.74, 17.75)

0.177

33 (32.04)

 

20 (19.42)

 

II

11.78 (6.56, 23.12)

12.32 (7.03, 25.09)

0.619

67 (42.14)

 

48 (30.19)

 

III

12.15 (6.60, 33.49)

13.43 (7.17, 27.80)

0.533

99 (41.77)

 

69 (29.11)

 
  1. *P value for Wilcoxon test; †P value for chi-square test